Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
41.81
+0.12 (0.29%)
Sep 11, 2026, 12:32 PM EDT - Market open
Supernus Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,430 | 2,850 | 1,997 | 1,581 | 1,928 | 1,551 | |
Market Cap Growth | -5.41% | 42.72% | 26.29% | -18.00% | 24.34% | 16.99% |
Enterprise Value | 2,098 | 2,611 | 1,632 | 1,398 | 1,849 | 1,128 |
Last Close Price | 41.69 | 49.70 | 36.16 | 28.94 | 35.67 | 29.16 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 27.03 | 1201.42 | 31.76 | 29.03 |
Forward PE | 11.90 | 19.33 | 19.65 | 15.34 | 30.84 | 15.73 |
PS Ratio | 2.92 | 3.96 | 3.02 | 2.60 | 2.89 | 2.68 |
PB Ratio | 2.35 | 2.68 | 1.93 | 1.72 | 2.18 | 1.90 |
P/TBV Ratio | 5.48 | 7.76 | 5.03 | 7.73 | 28.90 | - |
P/FCF Ratio | 128.99 | 61.96 | 11.66 | 14.30 | 16.56 | 12.40 |
P/OCF Ratio | 121.71 | 60.21 | 11.61 | 14.23 | 16.51 | 12.20 |
PEG Ratio | 0.49 | 0.51 | 1.11 | 1.11 | 1.11 | 1.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.52 | 3.63 | 2.47 | 2.30 | 2.77 | 1.95 |
EV/EBITDA Ratio | 18.94 | 22.25 | 11.51 | 14.23 | 14.10 | 10.06 |
EV/EBIT Ratio | 239.54 | 101.35 | 26.59 | 104.31 | 40.53 | 14.18 |
EV/FCF Ratio | 111.32 | 56.77 | 9.53 | 12.65 | 15.88 | 9.01 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.03 | 0.05 | 0.51 | 0.54 |
Debt / EBITDA Ratio | 0.32 | 0.31 | 0.22 | 0.37 | 3.13 | 3.55 |
Debt / FCF Ratio | 2.14 | 0.89 | 0.20 | 0.38 | 3.87 | 3.52 |
Net Debt / Equity Ratio | -0.32 | -0.25 | -0.40 | -0.25 | -0.12 | -0.02 |
Net Debt / EBITDA Ratio | -3.00 | -2.28 | -2.96 | -2.34 | -0.80 | -0.17 |
Net Debt / FCF Ratio | -17.67 | -5.82 | -2.45 | -2.08 | -0.90 | -0.15 |
Asset Turnover | 0.59 | 0.51 | 0.50 | 0.41 | 0.39 | 0.36 |
Inventory Turnover | 3.52 | 2.65 | 2.84 | 2.08 | 0.98 | 1.12 |
Quick Ratio | 1.68 | 1.47 | 2.04 | 1.38 | 0.91 | 1.55 |
Current Ratio | 2.08 | 1.91 | 2.35 | 1.70 | 1.07 | 1.91 |
Return on Equity (ROE) | -10.49% | -3.68% | 7.55% | 0.15% | 7.13% | 6.85% |
Return on Assets (ROA) | 0.39% | 1.14% | 2.90% | 0.56% | 1.68% | 3.11% |
Return on Invested Capital (ROIC) | 1.22% | 3.65% | 6.99% | 0.80% | 5.09% | 6.93% |
Return on Capital Employed (ROCE) | 0.80% | 2.30% | 5.70% | 1.40% | 4.50% | 5.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -4.53% | -1.35% | 3.70% | 0.08% | 3.15% | 3.45% |
FCF Yield | 0.78% | 1.61% | 8.58% | 6.99% | 6.04% | 8.07% |
Buyback Yield / Dilution | -1.67% | -0.88% | -0.81% | 10.01% | -13.47% | -1.24% |